Edgewise Therapeutics (EWTX) Net Equity Issued and Repurchased (2022 - 2025)
Edgewise Therapeutics (EWTX) reported Net Equity Issued and Repurchased of $262000.0 for Q2 2025, down 99.89% sequentially from $239.1 million in Q1 2024.
Edgewise Therapeutics (EWTX) Net Equity Issued and Repurchased (2022 - 2025) Analysis & Trends
Edgewise Therapeutics (EWTX) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $262000.0 in Q2 2025.
- For the quarter ending Q2 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $262000.0; the trailing twelve-month figure through Dec 2025 stood at $262000.0 (down 99.89% YoY), and the FY2025 full-year result was $187.4 million, down 21.65% from the prior year.
- Net Equity Issued and Repurchased declined to $262000.0 in Q2 2025, from $239.1 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $239.1 million in Q1 2024 to a low of -$555000.0 in Q4 2022.
- A 3-year average of $79.6 million and a median of $262000.0 in 2025 frame the typical range for Net Equity Issued and Repurchased.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 262,000.00 |
| Jun 30, 2025 | 262,000.00 |
| Mar 31, 2024 | 239.15 Mn |
| Mar 31, 2024 | 239.15 Mn |
| Dec 31, 2022 | -555,000.00 |
| Dec 31, 2022 | -555,000.00 |